Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

ClinicalTrials.gov ID: NCT06184750

Public ClinicalTrials.gov record NCT06184750. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 15, 2026, 6:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen has been shown to reduce breast density, even at reduced dosages, and is approved for the prevention of breast cancer.

Study identification

NCT ID: NCT06184750
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: National Cancer Institute (NCI); NIH
Enrollment: 200 participants

Conditions and interventions

Conditions

Interventions

Procedure · Other · Drug

Eligibility (public fields only)

Age range: 18 Years to 55 Years
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 26, 2024
Primary completion: Mar 30, 2028
Completion: Sep 29, 2028
Last update posted: Jul 26, 2026

2024 – 2028

United States locations

U.S. sites: 11
U.S. states: 9
U.S. cities: 9

Facility	City	State	ZIP	Site status
University of Arizona Cancer Center - Prevention Research Clinic	Tucson	Arizona	85719	Recruiting
Northwestern University	Chicago	Illinois	60611	Recruiting
University of Illinois College of Medicine - Chicago	Chicago	Illinois	60612	Recruiting
University of Kansas Cancer Center	Kansas City	Kansas	66160	Recruiting
Brigham and Women's Hospital	Boston	Massachusetts	02115	Withdrawn
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
University of Michigan Rogel Cancer Center	Ann Arbor	Michigan	48109	Recruiting
Washington University School of Medicine	St Louis	Missouri	63110	Recruiting
Case Western Reserve University	Cleveland	Ohio	44106	Recruiting
Medical University of South Carolina	Charleston	South Carolina	29425	Recruiting
UT MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06184750, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 26, 2026 · Synced Sep 15, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06184750 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →